

Camzyos

Pakistan · access guide

Camzyos access in Pakistan: the DRAP named-patient pathway

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Camzyos (mavacamten) is the first-in-class oral selective allosteric cardiac myosin inhibitor approved by the US Food and Drug Administration in April 2022 for adults with symptomatic NYHA class II to III obstructive hypertrophic cardiomyopathy. Manufactured by Bristol-Myers Squibb, the medicine reduces actin-myosin cross-bridge formation, lowering excessive cardiac contractility, reducing left ventricular outflow tract obstruction, and improving exercise capacity. The EXPLORER-HCM and VALOR-HCM pivotal trials demonstrated improvements in peak VO₂, NYHA class, and a substantial reduction in the proportion of patients meeting criteria for invasive septal reduction therapy. The medicine is dispensed only through the Camzyos REMS program in the US due to the risk of heart failure from systolic dysfunction. Camzyos is not registered with the Drug Regulatory Authority of Pakistan (DRAP), and access for Pakistani patients runs through the Special Provision personal-use import combined with rigorous local cardiology follow-up.

Why Pakistani patients ask about Camzyos

Pakistan's tertiary cardiology infrastructure includes Armed Forces Institute of Cardiology Rawalpindi, National Institute of Cardiovascular Diseases Karachi, Punjab Institute of Cardiology Lahore, Aga Khan University Hospital Karachi, Shifa International Hospital Islamabad, and the major private cardiac centers. These centers actively manage obstructive HCM patients on conventional therapy (beta-blockers, calcium channel blockers, disopyramide) and refer for septal reduction therapy where medically refractory. Camzyos offers a pharmacologic alternative to septal reduction therapy for many patients.

The DRAP Special Provision pathway for Camzyos

Pakistan's framework for unregistered-medicine import runs through DRAP under the Drugs Act 1976 and DRAP Act 2012. The Special Provision personal-use import is available where a DRAP-licensed cardiologist documents clinical necessity. For Camzyos, the FDA approval and the documented failure or intolerance of conventional therapy provide the clinical justification. A complete application includes the clinical justification letter, the physician's PMDC registration, the receiving institution, the dosing schedule with monitoring plan, and the chain-of-custody plan. DRAP processing is typically 10 to 25 business days.

Where Camzyos is dispensed in Pakistan

Tertiary cardiology centers handling oHCM include AFIC Rawalpindi, NICVD Karachi, PIC Lahore, AKUH Karachi, Shifa International Islamabad, and the major private cardiac centers. Camzyos is an oral capsule and does not require cold-chain handling. The dispensing pharmacy is the prescribing hospital's outpatient pharmacy or a DRAP-licensed specialty importer.

Real cost picture for Camzyos in Pakistan

US wholesale acquisition cost for Camzyos is approximately USD 89,500 per year. The Pakistani rupee trades at approximately 280 PKR to 1 USD, so the annual reference range converts to roughly PKR 25 million at current rates. International logistics for oral medicines runs USD 200 to USD 500 per shipment quarter. DRAP permit fees are nominal. Pakistani private insurance does not routinely reimburse personal imports.

Typical timeline for Camzyos in Pakistan

End-to-end, most Pakistani Camzyos cases complete within 3 to 6 weeks from physician decision to dispensed product. DRAP processing runs 10 to 25 business days. US-side sourcing and shipment runs 7 to 14 days. Refill cadence aligns to a quarterly reorder rhythm with serial echocardiographic monitoring.

What your physician needs to provide

For a Pakistani cardiologist prescribing Camzyos, the clinical justification letter documents the oHCM diagnosis with echocardiographic LVOT gradient, NYHA class II to III symptoms, the prior therapy course, the patient's LVEF baseline (must be 55 percent or greater per FDA label), the planned monitoring schedule (echocardiogram at baseline, 4, 8, 12 weeks, then every 12 weeks; LVEF monitoring; CYP2C19 genotyping where available), and the contingency plan for dose adjustment if LVEF drops below 50 percent. The physician's PMDC registration completes the package.

Common questions about Camzyos in Pakistan

Will Pakistani private insurance cover this? Pakistani private insurers do not routinely reimburse rare-disease personal imports. Cash-pay is the operating assumption.

How is the LVEF monitored? Serial echocardiograms at baseline, 4, 8, 12 weeks, then every 12 weeks. Dose adjustments are based on LVOT gradient and LVEF.

What about CYP2C19 genotyping? Mavacamten is metabolised primarily by CYP2C19. Poor metabolisers have higher exposure and lower starting doses are used. Genotype testing is available at AKUH and other major centers.

What if my LVEF drops? The FDA label requires treatment interruption if LVEF drops below 50 percent. After recovery, treatment can be resumed at a lower dose.

What about alternative therapy? Beta-blockers and disopyramide remain conventional options. Septal reduction therapy (surgical myectomy or alcohol septal ablation at experienced cardiac centers) is the invasive alternative.

Where Reserve Meds fits in Camzyos cases

Reserve Meds is a US-based concierge coordinator. For Camzyos cases originating in Pakistan, we orchestrate US-side sourcing through DSCSA-compliant channels, build the DRAP documentation packet your cardiologist submits, coordinate shipment, and assign a single named coordinator who works with your local cardiology team on the REMS-equivalent monitoring schedule. No prior Reserve Meds Camzyos case experience is logged yet at the Pakistan-origin profile.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com